Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/29/24
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 02/15/24
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®GlobeNewsWire • 11/09/23
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 10/24/23
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual ConferenceGlobeNewsWire • 10/18/23
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023GlobeNewsWire • 10/11/23
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway ExtendedGlobeNewsWire • 09/11/23
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/20/23
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal AntibodyGlobeNewsWire • 06/21/23
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023GlobeNewsWire • 06/21/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUSPRNewsWire • 05/11/23